Studies have confirmed the effectiveness of ctDNA methylation screening techniques

Fudan University Taizhou Institute of Health Sciences and human esophagic group research institute researcher Chen Xingdong team found that for colorectal cancer, esophageal cancer, liver cancer, lung cancer and stomach cancer, such as 5 common malignancies, before reaching the existing standard of clinical diagnosis, even before the patient has conscious symptoms, early cancer signal - trace tumor methylation is present in the blood circulation, and can be non-invasing detection, time can be 4 years earlier than conventional diagnosis.according to
, the researchers used the ctDNA methylation multi-cancer screening technology PanSeer method developed by Fudan alumni enterprisefar gene, and conducted a long-term, systematic early detection study of some blood samples from the Taizhou queue led by Fudan University, confirming that tumor markers can be detected earlier by increasing the sensitivity of detection technology, thus achieving effective early cancer screening.
, the morbidity and mortality of malignant tumors are increasing year by year, and have become one of the major disease burdens in the world. Verification and research of early oncology detection and screening requires not only efficient and sensitive techniques, but also, crucially, blood and biological samples of tumor patients before diagnosis.
, led by Fudan University, began construction in 2007. So far, nearly 200,000 community members have participated in the study. Through systematic queue follow-up, the research team tracked the occurrence of various major chronic diseases in the queue population for a long time, and collected more than 1.5 million biological samples of various types in multiple time nodes in the asymptomatic population for long-term preservation. The published study included blood samples from 191 patients who were diagnosed with tumors between 1 and 4 years after the sampling point, and 223 blood samples from tumor patients who were diagnosed at a local hospital, and followed a strict 1:1 matching principle, selecting 414 patient samples that followed for more than 10 years and were not diagnosed with tumors as a control population.
that the school-enterprise research team integrated life sciences and big data science multidisciplinary approach, based on ctDNA methylation traits to design a set of machine learning methods. Sensitivity to patient samples taken after diagnosis and before diagnosis was 88% and 91%, respectively.
study found that the chinese original technology for colorectal cancer, esophageal cancer, liver cancer, lung cancer and stomach cancer and other five different cancer detection sensitivity at different times before diagnosis of blood samples similar. This suggests that cancer signals are present in the blood early in the disease, even years before symptoms are diagnosed. Using samples from the Taizhou Prospective Queue, the Fudan team demonstrated that DNA methylation sequencing could detect cancer earlier than traditional diagnostic methods.
Jin Li, author of the research paper,
academician, director of the Taizhou Institute of Health Sciences of Fudan University and the Institute of Human Esothic Group, said that in the era of precision medicine and big data, large-scale population cohort research has become one of the main supporting platforms for biomedical research.
develop early screening tests for cancer in high-risk or community groups, and cost is a key factor in ensuring test availability and audience compliance. Chen Xingdong, the paper's first author, said the testing technology is still being further optimized and refined, and the findings will be validated in a larger population and in a multi-center queue across the country. (Source: Huang Xin, China Science Journal)
relevant paper information: